Biopharmaceutical Contract Manufacturing Market

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems for Biopharmaceuticals
3.3.1. Insect Expression Systems
3.3.2. Mammalian Expression Systems
3.3.3. Microbial Expression Systems
3.3.3.1. Bacterial Expression Systems
3.3.3.2. Fungal Expression Systems
3.3.3.3. Yeast Expression Systems
3.3.4. Plant Expression Systems
3.3.5. Mammalian versus Microbial Expression Systems

3.4. Manufacturing Process of Biopharmaceuticals
3.4.1. Upstream Processing
3.4.2. Fermentation
3.4.3. Downstream Processing

3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
3.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
3.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
3.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
3.7. Key Considerations While Selecting a Contract Manufacturing Partner
3.8. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Service(s) Offered
4.2.5. Analysis by Type of Biologic Manufactured
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Type of Expression System Used
4.2.8. Analysis by Type of Bioreactor Used
4.2.9. Analysis by Mode of Operation of Bioreactor

5. REGIONAL CAPABILITY ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Overall Landscape of Biopharmaceutical Contract Manufacturing Facilities
5.3.1. Analysis by Type of Service(s) Offered
5.3.2. Analysis by Scale of Operation
5.3.3. Analysis by Type of Expression System Used
5.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
5.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
5.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Regulatory Scenario of Biopharmaceutical Contract Manufacturing in the US
6.3. Leading Biopharmaceutical CMOs in North America

6.3.1. AGC Biologics
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.2.1. Process Development
6.3.1.2.2. cGMP Manufacturing
6.3.1.2.3. Quality and Regulatory
6.3.1.2.4. Process Validation
6.3.1.3. Financial Information
6.3.1.4. Manufacturing Facilities
6.3.1.5. Recent Developments and Future Outlook

6.3.2. Catalent (Catalent Pharma Solutions)
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.2.1. Cell Line Development
6.3.2.2.2. Manufacturing (Biomanufacturing)
6.3.2.2.3. ADCs and Bioconjugates Manufacturing
6.3.2.2.4. Biosimilars Development and Manufacturing
6.3.2.2.5. Proprietary Delivery and Fill / Finish Solutions
6.3.2.2.6. Analytical Services
6.3.2.3. Clinical Supply Services
6.3.2.4. Financial Information
6.3.2.5. Manufacturing Facilities
6.3.2.6. Recent Developments and Future Outlook

6.3.3. Cytiva (GE Healthcare)
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.2.1. Biomanufacturing Services
6.3.3.2.2. Scientific Support
6.3.3.2.3. OptiRun Service Solutions
6.3.3.2.4. Instruments Qualification Services
6.3.3.3. Financial Information
6.3.3.4. Manufacturing Facilities
6.3.3.5. Recent Developments and Future Outlook

6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.2.1. Strain Development
6.3.4.2.2. Process Development
6.3.4.2.3. GMP Contract Manufacturing
6.3.4.2.4. Analytical Solutions
6.3.4.3. Financial Information
6.3.4.4. Manufacturing Facilities
6.3.4.5. Recent Developments and Future Outlook

6.3.5. KBI Biopharma
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.2.1. Process Development
6.3.5.2.2. Analytical Development
6.3.5.2.3. GMP Manufacturing
6.3.5.2.4. Clinical Cell Therapy Support
6.3.5.3. Recent Developments and Future Outlook

6.3.6. Patheon (acquired by Thermo Fisher Scientific)
6.3.6.1 Company Overview
6.3.6.2. Service Portfolio
6.3.6.2.1. Biologics
6.3.6.2.1.1. Drug Substance
6.3.6.2.2. Analytical Services
6.3.6.2.3. Product Development
6.3.6.2.4. Commercial Product Supply
6.3.6.3. Financial Information
6.3.6.4. Manufacturing Facilities
6.3.6.5. Recent Developments and Future Outlook
6.3.7. Piramal Pharma Solutions
6.3.7.1 Company Overview
6.3.7.2. Service Portfolio
6.3.7.2.1. Antibody Drug Conjugation Services
6.3.7.2.2. Other Services
6.3.7.3. Financial Information
6.3.7.4. Manufacturing Facilities
6.3.7.5. Recent Developments and Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
7.2.1. EMA’s cGMP Regulations

7.3. Leading Biopharmaceutical CMOs in Europe

7.3.1. Boehringer Ingelheim (BioXcellence)
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.2.1. Process Development
7.3.1.2.1.1. Expression Systems
7.3.1.2.1.2. Upstream Technology
7.3.1.2.1.3. Downstream Technology
7.3.1.2.1.4. Other Process Development Services
7.3.1.2.2. Quality Assurance
7.3.1.2.3. Fill / Finish
7.3.1.3. Financial Information
7.3.1.4. Manufacturing Facilities
7.3.1.5. Recent Developments and Future Outlook

7.3.2. Lonza
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Manufacturing Services
7.3.2.4. Financial Information
7.3.2.5. Manufacturing Facilities
7.3.2.6. Recent Developments and Future Outlook
7.3.3. Novasep
7.3.3.1 Company Overview
7.3.3.2. Service Portfolio
7.3.3.2.1. Services for Viruses and Viral Vectors
7.3.3.2.2. Services for Monoclonal Antibodies
7.3.3.2.3. Services for ADCs
7.3.3.2.4. Quality, Regulatory and Other Services
7.3.3.3. Manufacturing Facilities
7.3.3.4. Recent Developments and Future Outlook

7.3.4. Olon
7.3.4.1. Company Overview
7.3.4.2. Service Portfolio
7.3.4.3. Manufacturing Facilities
7.3.4.4. Recent Developments and Future Outlook

7.3.5. Rentschler Biopharma
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.2.1. Bioprocess Development
7.3.5.2.2. Biomanufacturing Services
7.3.5.2.3. Other Services
7.3.5.3. Manufacturing Facilities
7.3.5.4. Recent Developments and Future Outlook

7.3.6. Sandoz
7.3.6.1. Company Overview
7.3.6.2. Service Portfolio
7.3.6.3. Financial Information
7.3.6.4. Recent Developments and Future Outlook

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND THE REST OF THE WORLD
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in China
8.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
8.2.2. Challenges Faced while Outsourcing to China
8.3. Leading Biopharmaceutical CMOs in China

8.3.1. WuXi Biologics
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Discovery Services
8.3.1.2.2. Development Services
8.3.1.2.3. Testing Services
8.3.1.2.4. Clinical Manufacturing Services
8.3.1.2.5. Fill / Finish Operations
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Recent Developments and Future Outlook

8.4. Biopharmaceutical Contract Manufacturing in India
8.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
8.4.2. Challenges Faced while Outsourcing to India

8.5. Leading Biopharmaceutical CMOs in India
8.5.1. Kemwell Biopharma
8.5.1.1. Company Overview
8.5.1.2. Service Portfolio
8.5.1.2.1. Development Services for Biopharmaceuticals
8.5.1.2.2. Manufacturing Services for Biopharmaceuticals
8.5.1.3. Manufacturing Facilities
8.5.1.4. Recent Developments and Future Outlook
8.6. Biopharmaceutical Contract Manufacturing in Japan
8.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario

8.7. Leading Biopharmaceutical CMOs in Japan
8.7.1. Minaris Regenerative Medicine
8.7.1.1. Company Overview
8.7.1.2. Service Portfolio
8.7.1.2.1. Manufacturing Development
8.7.1.2.2. GMP Manufacturing
8.7.1.3. Manufacturing Facilities
8.7.1.4. Recent Developments and Future Outlook

8.7.2. Takara Bio
8.7.2.1. Company Overview
8.7.2.2. Service Portfolio
8.7.2.3. Financial Information
8.7.2.4. Manufacturing Facilities
8.7.2.5. Recent Developments and Future Outlook

8.8. Biopharmaceutical Contract Manufacturing in South Korea
8.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
8.9. Leading Biopharmaceutical CMOs in South Korea
8.9.1. Celltrion
8.9.1.1. Company Overview
8.9.1.2. Service Portfolio
8.9.1.3. Financial Information
8.9.1.4. Manufacturing Facilities
8.9.1.5. Recent Developments and Future Outlook

8.9.2. Samsung BioLogics
8.9.2.1. Company Overview
8.9.2.2. Service Portfolio
8.9.2.2.1. Process Development
8.9.2.2.2. Analytical Services
8.9.2.2.3. cGMP Manufacturing Services
8.9.2.2.4. Aseptic Fill / Finish
8.9.2.2.5. Quality Services
8.9.2.2.6. Other Services
8.9.2.3. Financial Information
8.9.2.4. Manufacturing Facilities
8.9.2.5. Recent Developments and Future Outlook

8.10. Biopharmaceutical Contract Manufacturing in Australia
8.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
8.11. Leading Biopharmaceutical CMOs in Australia
8.11.1. Cell Therapies
8.11.1.1. Company Overview
8.11.1.2. Service Portfolio
8.11.1.3. Manufacturing Facilities
8.11.1.4. Recent Developments and Future Outlook

8.11.2. Luina Bio
8.11.2.1. Company Overview
8.11.2.2. Service Portfolio
8.11.2.2.1. Microbial Products
8.11.2.2.2. Vaccines
8.11.2.2.3. Support Services
8.11.2.2.4. Quality-related Services
8.11.2.3. Manufacturing Facilities
8.11.2.4. Recent Developments and Future Outlook

9. NICHE BIOPHARMACEUTICAL SECTORS
9.1. Chapter Overview
9.2. Bispecific Antibodies
9.2.1. Introduction
9.2.2. Pipeline Analysis
9.2.2.1. Bispecific Antibody Therapeutics: Clinical Pipeline
9.2.2.2. Bispecific Antibody Therapeutics: Early Stage Pipeline
9.2.2.3. Multivalent Drug Candidates
9.2.3. Analysis by Phase of Development
9.2.4. Analysis by Target Indication
9.2.5. Bispecific Antibody Therapeutics: List of Technology Providers
9.2.6. Key Manufacturing Considerations and Challenges
9.2.7. Contract Manufacturing Scenario
9.2.7.1. CMOs Offering Services for Bispecific Antibodies

9.3. Antibody Drug Conjugates (ADCs)
9.3.1. Components of ADCs
9.3.1.1. Antibody
9.3.1.2. Cytotoxin
9.3.1.3. Linker
9.3.2. Manufacturing Process
9.3.3. Pipeline Analysis
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Target Indication
9.3.6. Key Technology Players: Analysis by Number of ADC Therapeutics
9.3.7. Novel Drug Conjugates
9.3.8. Key Manufacturing Considerations and Challenges
9.3.9. Contract Manufacturing Scenario
9.3.9.1. CMOs Offering Services for ADCs

9.4. Cell Therapies
9.4.1. Introduction
9.4.2. Current Market Landscape
9.4.3. Cell Therapy Manufacturing
9.4.3.1. Cell Therapy Manufacturing Models
9.4.3.1.1. Centralized Manufacturing
9.4.3.1.2. Decentralized Manufacturing

9.4.4. Key Manufacturing Considerations and Challenges
9.4.5. Factors Influencing Cell Therapy Manufacturing
9.4.5.1. Characterization
9.4.5.2. Cost of Goods
9.4.5.3. Automation of Cell Therapy Manufacturing
9.4.6. Analysis by Types of Cells Manufactured
9.4.7. Stem Cell Therapies: Analysis by Phase of Development
9.4.8. T-Cell Therapies: Analysis by Phase of Development
9.4.9. Contract Manufacturing Scenario
9.4.9.1. CMOs Offering Services for Cell Therapy

9.5. Gene Therapies
9.5.1. Gene Therapies Market: Pipeline Analysis
9.5.1.1. Analysis by Stage of Development
9.5.1.2. Analysis by Phase of Development
9.5.1.3. Analysis by Type of Vector Used
9.5.1.3.1. Clinical Pipeline
9.5.1.3.2. Preclinical Pipeline
9.5.1.4. Analysis by Target Indication
9.5.1.4.1. Clinical and Commercial Pipeline
9.5.1.4.1. Preclinical Pipeline
9.5.1.5. Analysis by Location of Manufacturing Facility
9.5.1.6 Analysis by Type of Viral Vector Used
9.5.2. Contract Manufacturing Scenario
9.5.2.1. CMOs Offering Services for Viral Vectors

9.6. Plasmid DNA
9.6.1. Introduction
9.6.2. Analysis by Location of Manufacturing Facility
9.6.3. Contract Manufacturing Scenario
9.6.3.1. CMOs Offering Services for Plasmid DNA

10. CASE STUDY: OUTSOURCING OF BIOSIMILARS
10.1. Chapter Overview
10.2. Biosimilars: An Introduction
10.3. Biosimilars: Development Stages
10.4. Regulatory Requirements for Licensing of Biosimilars
10.5. Need for Outsourcing Biosimilar Development and Manufacturing
10.6. Impact of Biosimilars on the Global Contract Manufacturing Market
10.6.1. Biosimilars: Historical Trend of FDA Approval
10.7. Biosimilars Contract Manufacturing Service Providers
10.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

11. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
11.1. Chapter Overview
11.2. Small Molecule and Large Molecule Drugs / Therapies
11.2.1. Comparison of General Characteristics
11.2.2. Comparison of Key Specifications
11.2.3. Comparison of Manufacturing Process
11.2.4. Comparison of Key Manufacturing Challenges

12. CASE STUDY: IN-HOUSE MANUFACTURING
12.1. Chapter Overview
12.2. In-House Manufacturing
12.2.1. Benefits Associated with In-House Manufacturing
12.2.2. Risks Associated with In-House Manufacturing
12.3. Outsourcing Trends in the Biopharmaceutical Industry
12.3.1. Types of Outsourcing Partners

12.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
12.4.1. Approved Biologics: Analysis by Company Size and Type of Manufacturing Model Adopted
12.4.2. Approved Biologics: Analysis by Company Size and Type of Biologic Manufactured
12.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.3.1. Scenario 1
13.3.2. Scenario 2
13.3.3. Scenario 3
13.3.4. Scenario 4
13.4. Conclusion

14. BIG PHARMA INITIATIVES
14.1. Chapter Overview
14.2. Biopharmaceutical Related Initiatives of Big Pharmaceutical Players
14.2.1. Analysis by Number of Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Purpose of Initiative
14.2.4. Analysis by Type of Initiative
14.2.4.1. Analysis by Type of Partnership
14.2.4.2. Analysis by Type of Expansion
14.2.5. Analysis by Scale of Operation
14.2.6. Analysis by Type of Biologic Manufactured
14.2.7. Analysis by Year of Initiative and Company
14.2.8. Analysis by Purpose of Initiative and Company
14.2.9. Analysis by Year and Type of Initiative
14.2.10. Analysis by Region of Expansion and Company
14.2.11. Analysis by Type of Biologic Manufactured and Company
14.3. Competitive Benchmarking of Big Pharma Players

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Biologic Manufactured
15.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
15.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
15.3.7. Analysis by Type of Biologic Manufactured and Geography
15.3.8. Analysis by Therapeutic Area
15.3.9. Most Active Players: Analysis by Number of Partnerships
15.3.10. Analysis by Region
15.3.10.1. Intracontinental and Intercontinental Agreements
15.3.10.2. Local and International Agreements

16. MERGERS AND ACQUISITIONS
16.1. Chapter Overview
16.2. Merger and Acquisition Models
16.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
16.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
16.3.2. Analysis by Type of Acquisition
16.3.3. Analysis by Region
16.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
16.3.3.2. Mergers and Acquisitions: Country-wise Distribution
16.3.3.3. Mergers and Acquisitions: Year-wise Trend in North America, Europe and Asia-Pacific
16.3.4 Most Active Acquirers: Analysis by Number of Acquisitions
16.3.5 Analysis by Key Value Drivers
16.3.6. Analysis by Year of Acquisition and Key Value Drivers
16.3.7. Analysis by Type of Biologic Manufactured
16.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
16.4. Key Acquisitions: Deal Multiples
16.4.1. Year-wise Trend of Deal Multiple Amount

17. RECENT EXPANSIONS
17.1. Chapter Overview
17.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
17.2.1. Analysis by Year of Expansion
17.2.2. Analysis by Purpose of Expansion
17.2.3. Analysis by Year and Purpose of Expansion
17.2.4. Analysis by Type of Biologic Manufactured
17.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
17.2.6. Analysis by Location of Expanded Facility
17.2.7. Most Active Players: Analysis by Number of Recent Expansions
17.2.8. Analysis by Purpose of Expansion and Location of Expanded Facility
17.2.9. Analysis by Amount Invested
17.2.10. Recent Expansions: 2016-2020 and 2016-2022 Scenario

18. RECENT DEVELOPMENTS
18.1. Chapter Overview
18.2. Types of Funding
18.3. Biopharmaceutical Contract Manufacturing: Funding and Investments
18.3.1. Cumulative Year-wise Distribution by Number of Instances
18.3.2. Cumulative Year-wise Distribution of Amount Invested
18.3.3. Analysis of Instances by Type of Funding
18.3.4. Analysis of Total Amount Invested by Type of Funding
18.3.5. Analysis by Year and Type of Funding
18.3.6. Regional Analysis of Total Amount Invested and Number of Funding Instances (Continent-wise)
18.3.7. Regional Analysis of Total Amount Invested and Number of Funding Instances (Country-wise)
18.3.8. Most Active Players: Analysis by Number of Funding Instances
18.3.9. Most Active Players: Analysis by Total Amount Raised
18.3.10. Most Active Investors: Analysis by Number of Funding Instances
18.4. Technological Advancements
18.4.1. Single Use Technology
18.4.2. Process Analytical Technology (PAT)
18.4.3. Continuous Processing
18.4.4. Quality by Design (QbD) in Bio-Processing
18.4.5. Modular / Podular Biopharma Facilities

19. CAPACITY ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity
19.3.1. Analysis by Company Size
19.3.2. Analysis by Type of Expression System Used
19.3.3. Analysis by Scale of Operation
19.3.4. Analysis by Region
19.3.4.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
19.3.4.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
19.3.4.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
19.4. Concluding Remarks

20. DEMAND ANALYSIS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Global Demand for Biopharmaceuticals
20.3.1. Analysis by Therapeutic Area
20.4. Relationship Between Annual Demand and Capacity
20.5. Annual Demand for Emerging Novel Biologics
20.5.1. ADC Therapeutics: Overall Annual Demand
20.5.2. ADC Therapeutics: Demand and Supply Analysis
20.6. Global Demand for Cell Therapy Manufacturing

21. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS
21.1. Chapter Overview
21.2. Key Parameters
21.3. Assumptions and Methodology
21.4. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2022-2042
21.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX and OPEX, 2023-2042
21.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, 2023-2042
21.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, 2023-2042

22. MARKET FORECAST AND OPPORTUNITY ANALYSIS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology

22.3. Global Biopharmaceutical Contract Manufacturing Market, 2022-2035
22.4. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Service(s) Offered
22.4.1. Biopharmaceutical Contract Manufacturing Market for APIs, 2022-2035
22.4.2. Biopharmaceutical Contract Manufacturing Market for FDFs, 2022-2035

22.5. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Biologic Manufactured
22.5.1. Biopharmaceutical Contract Manufacturing Market for Antibodies, 2022-2035
22.5.2. Biopharmaceutical Contract Manufacturing Market for Cell Therapies, 2022-2035
22.5.3. Biopharmaceutical Contract Manufacturing Market for Vaccines, 2022-2035
22.5.4. Biopharmaceutical Contract Manufacturing Market for Other Biologics, 2022-2035

22.6. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Expression System Used
22.6.1. Biopharmaceutical Contract Manufacturing Market for Mammalian Cell-based Operations, 2022-2035
22.6.2. Biopharmaceutical Contract Manufacturing Market for Microbial Cell-based Operations, 2022-2035
22.6.3. Biopharmaceutical Contract Manufacturing Market for Other Expression System-based Operations, 2022-2035
22.7. Biopharmaceutical Contract Manufacturing Market: Analysis by Scale of Operation
22.7.1. Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, 2022-2035
22.7.2. Biopharmaceutical Contract Manufacturing Market for Commercial Operations, 2022-2035
22.8. Biopharmaceutical Contract Manufacturing Market: Analysis by Company Size, 2022-2035
22.8.1. Biopharmaceutical Contract Manufacturing Market for Small Companies, 2022-2035
22.8.2. Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, 2022-2035
22.8.3. Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, 2022-2035

22.9. Biopharmaceutical Contract Manufacturing Market: Analysis by Geography
22.9.1. Biopharmaceutical Contract Manufacturing Market in North America, 2022-2035
22.9.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2022-2035
22.9.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2022-2035

22.9.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2022-2035
22.9.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2022-2035
22.9.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2022-2035
22.9.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2022-2035
22.9.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2022-2035
22.9.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2022-2035
22.9.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2022-2035

22.9.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2022-2035
22.9.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2022-2035
22.9.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2022-2035
22.9.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2022-2035
22.9.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2022-2035
22.9.3.5. Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2022-2035
22.9.4. Biopharmaceutical Contract Manufacturing Market in Latin America, 2022-2035
22.9.5. Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2022-2035

23. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES
23.1. Chapter Overview
23.2. Historical Evolution of the Virtual Business Model
23.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
23.4. Advantages Associated with Outsourcing Operations to Service Providers
23.5. Key Challenges Associated with Outsourcing Operations to Service Providers

24. SWOT ANALYSIS
24.1 Chapter Overview
24.2. Strengths
24.3. Weaknesses
24.4. Opportunities
24.5. Threats
24.6. Comparison of SWOT Factors
24.7. Conclusion

25. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
25.1. Chapter Overview
25.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
25.3. Shift from One-time Contracts to Strategic Partnerships
25.4. Integration / Adoption of Innovative Technologies
25.4.1. Single use Bioreactors
25.4.2. Novel Bioprocess Techniques
25.4.3. Bioprocess Automation
25.5. Focus on Niche Therapeutic Areas
25.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
25.7. Capability and Expertise Expansions by CMOs to become One-Stop-Shops
25.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
25.9. Increase in Financial Inflow and Outsourcing Budgets
25.10. Challenges Faced by both Sponsors and Service Providers
25.10.1. Concerns Related to Single Use Systems
25.10.2. Issues Related to Capacity Fluctuations
25.11. Concluding Remarks

26. SURVEY ANALYSIS
26.1. Chapter Overview
26.1.1. Overview of Respondents
26.1.2. Analysis by Designation of Respondents
26.2. Analysis by Biologic Manufacturing Expertise
26.3. Analysis by Scale of Manufacturing
26.4. Analysis by Location of Production Facilities
26.5. Analysis by Type of Expression System Used
26.6. Analysis by Type of Bioreactor Used
26.7. Analysis by Mode of Operation of Bioreactor

27. CONCLUSION
27.1. Chapter Overview

28. INTERVIEW TRANSCRIPTS
28.1. Chapter Overview
28.2. Andrea Conforto, Sales & Marketing, Bioservices Director, Olon
28.3. Astrid Brammer, Key Account Manager, Richter Helm
28.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
28.5. Christian Bailly, ex-Director of CDMO, Pierre Fabre
28.6. Claire Otjes, Communication Manager, Batavia Biosciences
28.7. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
28.8. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
28.9. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
28.10. Jeffrey Hung, General Manager, Vigene Biosciences
28.11. Kevin Daley, Director Pharmaceuticals, Novasep
28.12. Mark Wright, ex-Site Head, Grangemouth, Piramal Healthcare
28.13. Max Rossetto, General Manager – Business Development, Luina Bio
28.14. Nicolas Grandchamp, R&D Leader, GEG Tech
28.15. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
28.16. Sebastian Schuck, Head of Business Development, Wacker Biotech
28.17. Tatjana Buchholz, Marketing Manager, Plasmid Factory and Marco Schmeer, ex-Project Manager
28.18. Tim Oldham, ex- Chief Executive Officer, Cell Therapies
28.19. Traci Kyes, Vice President of Commercial Operations, Arranta Bio
28.20. Vijayakumar Ramaraj, Chief Manager, Shilpa Biologicals

29. APPENDIX I: TABULATED DATA

30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Mergers and Acquisitions
Figure 2.4 Executive Summary: Recent Expansions
Figure 2.5 Executive Summary: Demand Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Biopharmaceuticals
Figure 3.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 3.3 Stages of the Biomanufacturing Process
Figure 3.4 Types of Third-Party Service Providers
Figure 3.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 4.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 4.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biopharmaceutical Contract Manufacturers: Distribution by Company Size, Year of Establishment and Location of Headquarters
Figure 4.6 Biopharmaceutical CMOs: Distribution by Type of Service(s) Offered
Figure 4.7 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured
Figure 4.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters
Figure 4.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Figure 4.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 4.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 4.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 4.13 Biopharmaceutical Contract Manufacturers: Distribution by Types of Expression Systems Used and Location of Headquarters
Figure 4.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Figure 4.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Figure 5.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 5.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service(s) Offered
Figure 5.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 5.4 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Expression System Used
Figure 5.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturers in North America
Figure 5.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturers in Europe
Figure 5.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturers in Asia-Pacific and Rest of the World
Figure 6.1 Biopharmaceutical Industry: The US Market Scenario
Figure 6.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 6.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 6.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 6.5 AGC Biologics: Annual Revenues, FY 2017-Q1 2022 (JPY Billion)
Figure 6.6 Catalent: Service Portfolio
Figure 6.7 Catalent: Biosimilars Service Portfolio
Figure 6.8 Catalent: Annual Revenues, FY 2017-9M 2022 (USD Million)
Figure 6.9 Cytiva: Service Portfolio
Figure 6.10 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
Figure 6.11 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.12 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2017-FY 2021 (JPY Billion)
Figure 6.13 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Figure 6.14 KBI Biopharma: Service Portfolio
Figure 6.15 Patheon: Service Portfolio
Figure 6.16 Patheon: Services and Solutions for Biologics
Figure 6.17 Patheon: Annual Revenues, FY 2017-FY 2021 (USD Million)
Figure 6.18 Piramal Enterprises: Annual Revenues, FY 2017-FY 2021 (INR Crores)
Figure 7.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 7.2 EMA GMP Guidelines: Key Considerations of the Contract Giver, Contract Acceptor and the Contract
Figure 7.3 Boehringer Ingelheim: Service Portfolio
Figure 7.4 Boehringer Ingelheim: Annual Revenues, FY 2017-FY 2021 (EUR Billion)
Figure 7.5 Lonza: Service Portfolio
Figure 7.6 Lonza: Annual Revenues, FY 2017-FY 2021 (CHF Billion)
Figure 7.7 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Figure 7.8 Novasep: Product Portfolio
Figure 7.9 Rentschler Biopharma: Service Portfolio
Figure 7.10 Sandoz: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 8.1 Chinese Regulatory Guidelines: Key Considerations of the Contract Giver
Figure 8.2 Chinese Regulatory Guidelines: Key Considerations of the Contract Acceptor
Figure 8.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 8.4 Biopharmaceutical Contract Manufacturing in China: Challenges
Figure 8.5 WuXi Biologics: Service Portfolio
Figure 8.6 Wuxi Biologics: Annual Revenues, FY 2017-FY 2021 (RMB Million)
Figure 8.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 8.8 Biopharmaceutical Contract Manufacturing in India: Challenges
Figure 8.9 Minaris Regenerative Medicine: Service Portfolio
Figure 8.10 Takara Bio: Service Portfolio
Figure 8.11 Takara Bio: Annual Revenues, FY 2017-FY 2021 (JPY Million)
Figure 8.12 Celltrion: Service Portfolio
Figure 8.13 Celltrion: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Figure 8.14 Samsung BioLogics: Service Portfolio
Figure 8.15 Samsung BioLogics: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Figure 8.16 Cell Therapies: Service Portfolio
Figure 8.17 Luina Bio: Service Portfolio
Figure 9.1 Structure of a Bispecific Antibody
Figure 9.2 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Figure 9.3 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Figure 9.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 9.5 Antibody Drug Conjugates: Distribution by Status of Development
Figure 9.6 Antibody Drug Conjugates: Distribution by Target Indication
Figure 9.7 Key ADC Technology Providers: Distribution by Number of Candidates
Figure 9.8 Decentralized Manufacturing: Process Model
Figure 9.9 Cell Therapy Manufacturing: Challenges and Growth Drivers
Figure 9.10 Cell Therapy: Potency as Critical Quality Attribute
Figure 9.11 Stem Cell Therapies: Distribution by Phase of Development
Figure 9.12 T-Cell Therapies: Distribution by Phase of Development
Figure 9.13 Gene Therapies: Distribution by Stage of Development
Figure 9.14 Gene Therapies: Distribution by Phase of Development
Figure 9.15 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 9.16 Early-Stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 9.17 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 9.18 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 9.19 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 9.20 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 10.1 Manufacturing Stages of a Biosimilar Product
Figure 10.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 10.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 10.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 10.5 Biosimilars: Historical Trend of FDA Approval, 2015-2021
Figure 10.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 11.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2021
Figure 11.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 12.1 Benefits Associated with In-House Manufacturing
Figure 12.2 Risks Associated with In-House Manufacturing
Figure 12.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 13.1 Make versus Buy Decision Making Framework
Figure 13.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 14.1 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2022
Figure 14.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 14.3 Big Pharma Players: Distribution by Purpose of Initiative
Figure 14.4 Big Pharma Players: Distribution by Type of Initiative
Figure 14.5 Big Pharma Players: Distribution by Type of Partnership
Figure 14.6 Big Pharma Players: Distribution by Type of Expansion
Figure 14.7 Big Pharma Players: Distribution by Scale of Operation
Figure 14.8 Big Pharma Players: Distribution by Type of Biologic Manufactured
Figure 14.9 Big Pharma Players: Distribution by Year of Initiative and Company (Heat Map Representation)
Figure 14.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
Figure 14.11 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 14.12 Big Pharma Players: Distribution by Region of Expansion and Company
Figure 14.13 Big Pharma Players: Distribution by Type of Biologic Manufactured and Company
Figure 14.14 Big Pharma Players: Distribution of Top Pharmaceutical Companies (Heat Map Representation)
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 15.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Figure 15.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Figure 15.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.9 Most Active Players: Distribution by Number of Partnerships
Figure 15.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 15.11 Partnerships and Collaborations: Local and International Agreements
Figure 16.1 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2022)
Figure 16.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 16.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 16.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 16.5 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015- 2022)
Figure 16.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 16.7 Catalent Biologics: Information on Key Acquisitions
Figure 16.8 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 16.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 16.10 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Figure 16.11 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Figure 16.12 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2022
Figure 17.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 17.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 17.4 Recent Expansions: Distribution by Type of Biologic Manufactured
Figure 17.5 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Figure 17.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 17.7 Most Active Players: Distribution by Number of Recent Expansions
Figure 17.8 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 17.9 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 17.10 Recent Expansions: Regional Comparison 2016-2020 and 2016-2022 Scenario
Figure 18.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Number of Funding Instances, 2016-2022
Figure 18.2 Funding and Investments: Cumulative Year-wise Trend of Total Amount Invested, 2016-2022 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 18.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 18.6 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Continent-wise) (USD Million)
Figure 18.7 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Country-wise) (USD Million)
Figure 18.8 Most Active Players: Distribution by Number of Funding Instances
Figure 18.9 Most Active Players: Distribution by Total Amount Invested (USD Million)
Figure 18.10 Most Active Investors: Analysis by Number of Funding Instances
Figure 19.1 Capacity Analysis: Distribution by Company Size
Figure 19.2 Capacity Analysis: Distribution by Type of Expression System Used
Figure 19.3 Capacity Analysis: Distribution by Scale of Operation
Figure 19.4 Capacity Analysis: Distribution by Region
Figure 19.5 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 19.6 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 19.7 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Figure 20.1 Global Demand for Biopharmaceuticals, 2022-2035 (in kilograms)
Figure 20.2 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Figure 20.3 Demand and Supply Scenario for Biopharmaceuticals, 2022-2035 (Million Liters)
Figure 20.4 Demand Analysis: Annual Demand for ADC Therapeutics (in kilograms), 2022-2030
Figure 20.5 ADC Therapeutics: Demand and Supply Scenario, 2022-2030
Figure 20.6 Global Demand for Cell Therapies, 2022-2030 (in terms of Number of Patients)
Figure 20.7 Global Demand for Cell Therapies, 2022-2030 (Billion Cells)
Figure 21.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 21.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 21.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2022-2042 (USD Million)
Figure 21.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Figure 21.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023: Distribution by CAPEX (USD Million)
Figure 21.6 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023-2042: Distribution by OPEX (USD Million)
Figure 22.1 Global Biopharmaceutical Contract Manufacturing Market, 2022-2035 (USD Billion)
Figure 22.2 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service(s) Offered
Figure 22.3 Biopharmaceutical Contract Manufacturing Market for APIs, 2022-2035 (USD Billion)
Figure 22.4 Biopharmaceutical Contract Manufacturing Market for FDFs, 2022-2035 (USD Billion)
Figure 22.5 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Figure 22.6 Biopharmaceutical Contract Manufacturing Market for Antibodies, 2022-2035 (USD Billion)
Figure 22.7 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, 2022-2035 (USD Billion)
Figure 22.8 Biopharmaceutical Contract Manufacturing Market for Vaccines, 2022-2035 (USD Billion)
Figure 22.9 Biopharmaceutical Contract Manufacturing Market for Other Biologics, 2022-2035 (USD Billion)
Figure 22.10 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
Figure 22.11 Biopharmaceutical Contract Manufacturing Market for Mammalian Cell-based Operations, 2022-2035 (USD Billion)
Figure 22.12 Biopharmaceutical Contract Manufacturing Market for Microbial Cell-based Operations, 2022-2035 (USD Billion)
Figure 22.13 Biopharmaceutical Contract Manufacturing Market for Other Expression System-based Operations, 2022-2035 (USD Billion)
Figure 22.14 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
Figure 22.15 Biopharmaceutical Contract Manufacturing Market for Clinical Operations, 2022-2035 (USD Billion)
Figure 22.16 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, 2022-2035 (USD Billion)
Figure 22.17 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
Figure 22.18 Biopharmaceutical Contract Manufacturing Market for Small Companies, 2022-2035 (USD Billion)
Figure 22.19 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, 2022-2035 (USD Billion)
Figure 22.20 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, 2022-2035 (USD Billion)
Figure 22.21 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography
Figure 22.22 Biopharmaceutical Contract Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 22.23 Biopharmaceutical Contract Manufacturing Market in the US, 2022-2035 (USD Billion)
Figure 22.24 Biopharmaceutical Contract Manufacturing Market in Canada, 2022-2035 (USD Billion)
Figure 22.25 Biopharmaceutical Contract Manufacturing Market in Europe, 2022-2035 (USD Billion)
Figure 22.26 Biopharmaceutical Contract Manufacturing Market in Italy, 2022-2035 (USD Billion)
Figure 22.27 Biopharmaceutical Contract Manufacturing Market in Germany, 2022-2035 (USD Billion)
Figure 22.28 Biopharmaceutical Contract Manufacturing Market in France, 2022-2035 (USD Billion)
Figure 22.29 Biopharmaceutical Contract Manufacturing Market in Spain, 2022-2035 (USD Billion)
Figure 22.30 Biopharmaceutical Contract Manufacturing Market in the UK, 2022-2035 (USD Billion)
Figure 22.31 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2022-2035 (USD Billion)
Figure 22.32 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 22.33 Biopharmaceutical Contract Manufacturing Market in China, 2022-2035 (USD Billion)
Figure 22.34 Biopharmaceutical Contract Manufacturing Market in India, 2022-2035 (USD Billion)
Figure 22.35 Biopharmaceutical Contract Manufacturing Market in South Korea, 2022-2035 (USD Billion)
Figure 22.36 Biopharmaceutical Contract Manufacturing Market in Japan, 2022-2035 (USD Billion)
Figure 22.37 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2022-2035 (USD Billion)
Figure 22.38 Biopharmaceutical Contract Manufacturing Market in Latin America, 2022-2035 (USD Billion)
Figure 22.39 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 23.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 23.2 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2022 (USD Billion)
Figure 24.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 24.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Figure 24.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 26.1 Survey Analysis: Distribution of Respondents by Company Type
Figure 26.2 Survey Analysis: Distribution of Respondents by Location of Headquarters
Figure 26.3 Survey Analysis: Distribution of Respondents by Designation
Figure 26.4 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Figure 26.5 Survey Analysis: Distribution by Scale of Manufacturing
Figure 26.6 Survey Analysis: Distribution by Location of Production Facilities
Figure 26.7 Survey Analysis: Distribution by Type of Expression System Used
Figure 26.8 Survey Analysis: Distribution by Type of Bioreactor Used
Figure 26.9 Survey Analysis: Distribution by Mode of Operation of Bioreactor
Figure 27.1 Concluding Remarks: Overall Market Landscape
Figure 27.2 Concluding Remarks: Partnerships and Collaborations
Figure 27.3 Concluding Remarks: Mergers and Acquisitions
Figure 27.4 Concluding Remarks: Recent Expansions
Figure 27.5 Concluding Remarks: Capacity Analysis
Figure 27.6 Concluding Remarks: Demand Analysis
Figure 27.7 Concluding Remarks: Market Forecast and Opportunity Analysis
Figure 27.8 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Mammalian versus Microbial Expression Systems
Table 4.1 List of Biopharmaceutical Contract Manufacturers
Table 4.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service(s) Offered
Table 4.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 4.4 Biopharmaceutical CMOs: Information on Scale of Operation
Table 4.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression Systaem Used
Table 4.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 4.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 5.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 5.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 5.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Biologics Manufacturing Facilities
Table 6.3 AGC Biologics: Recent Developments and Future Outlook
Table 6.4 Catalent: Company Overview
Table 6.5 Catalent: Biologics Manufacturing Facilities
Table 6.6 Catalent: Recent Developments and Future Outlook
Table 6.7 Cytiva: Company Overview
Table 6.8 Cytiva: Manufacturing Facilities
Table 6.9 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.10 FUJIFILM Diosynth Biotechnologies: Biopharmaceutical Facilities
Table 6.11 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.12 KBI Biopharma: Company Overview,
Table 6.13 KBI Biopharma: Overview of Manufacturing Capabilities
Table 6.14 KBI Biopharma: Recent Developments and Future Outlook
Table 6.15 Patheon: Company Overview
Table 6.16 Patheon: Biopharmaceutical Manufacturing and Development Facilities
Table 6.17 Patheon: Future Outlook
Table 6.18 Piramal Pharma Solutions: Company Overview
Table 6.19 Piramal Pharma Solutions: Facilities
Table 6.20 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 7.1 FDA Quality Agreement and EMA cGMP Regulations: A Comparative Analysis
Table 7.2 Boehringer Ingelheim: Company Overview
Table 7.3 Boehringer Ingelheim: Biopharmaceutical Facilities
Table 7.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 7.5 Lonza: Company Overview
Table 7.6 Lonza: Biopharmaceutical Facilities
Table 7.7 Lonza: Recent Developments and Future Outlook
Table 7.8 Novasep: Company Overview
Table 7.9 Novasep: Biologics Manufacturing Facilities
Table 7.10 Novasep: Recent Developments and Future Outlook
Table 7.11 Olon: Company Overview
Table 7.12 Olon: Biopharmaceutical Facilities
Table 7.13 Olon: Recent Developments and Future Outlook
Table 7.14 Rentschler Biopharma: Company Overview
Table 7.15 Rentschler Biopharma: Recent Developments and Future Outlook
Table 7.16 Sandoz: Company Overview
Table 8.1 WuXi Biologics: Company Overview
Table 8.2 WuXi Biologics: Recent Developments and Future Outlook
Table 8.3 Kemwell Biopharma: Company Overview
Table 8.4 Kemwell Biopharma: Recent Developments and Future Outlook
Table 8.5 Minaris Regenerative Medicine: Company Overview
Table 8.6 Minaris Regenerative Medicine: Manufacturing Facilities
Table 8.7 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 8.8 Takara Bio: Company Overview
Table 8.9 Takara Bio: Biologics Manufacturing Facilities
Table 8.10 Takara Bio: Recent Developments and Future Outlook
Table 8.11 Celltrion: Company Overview
Table 8.12 Celltrion: Biologics Manufacturing Facilities
Table 8.13 Celltrion: Recent Developments and Future Outlook
Table 8.14 Samsung BioLogics: Company Overview
Table 8.15 Samsung BioLogics: Biopharmaceutical Facilities
Table 8.16 Samsung BioLogics: Recent Developments and Future Outlook
Table 8.17 Cell Therapies: Company Overview
Table 8.18 Cell Therapies: Recent Developments and Future Outlook
Table 8.19 Luina Bio: Company Overview
Table 8.20 Luina Bio: Recent Developments and Future Outlook
Table 9.1 Bispecific Antibody Therapeutics: Information on Developer(s), Platform / Technology Used, Phase of Development, Target Antigens and Antibody Format
Table 9.2 Bispecific Antibody Therapeutics: Information on Developer(s), Technology Used, Phase of Development, Target Antigens, Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
Table 9.3 List of Other Emerging Multivalent Drug Candidates
Table 9.4 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 9.5 Bispecific Antibody Contract Manufacturers: List of Companies
Table 9.6 Commonly Used Cytotoxins for ADC Therapeutics
Table 9.7 Occupational Exposure Limit Bands, Safebridge Consultants
Table 9.8 Antibody Drug Conjugates: Drug Pipeline
Table 9.9 Novel Drug Conjugates: List of Developers
Table 9.10 ADC Contract Manufacturers: List of Companies
Table 9.11 Applications of Cell-based Therapies
Table 9.12 Cell-based Therapies: Commercialized Products,
Table 9.13 Assessments for Key Cell Therapy Manufacturing Steps
Table 9.14 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 9.15 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 9.16 Cell Therapy Contract Manufacturers: List of Cell Therapy Contract Manufacturers
Table 9.17 Cell Therapy Contract Manufacturers: List of Non-Industry Players
Table 9.18 Viral Vectors Manufacturers: Information on Type of Viral Vector Used
Table 9.19 Viral Vectors Contract Manufacturers: List of Companies,
Table 9.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 10.1 List of Biosimilars Contract Manufacturing Service Providers
Table 11.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 11.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 11.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 12.1 List of FDA Approved Biologics (2016-2022)
Table 14.1 Big Pharma Players: List of Biopharmaceutical Manufacturing Initiatives
Table 15.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2015-2022
Table 15.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 16.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015-2022
Table 16.2 Biopharmaceutical Contract Manufacturing Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured, 2015- 2022
Table 16.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2022
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions
Table 18.1 Biopharmaceutical Contract Manufacturing Market: Funding and Investment
Table 18.2 Funding and Investment Analysis: Summary of Investments
Table 18.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 19.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
Table 19.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 19.3 Capacity Analysis: Average Capacity for Mammalian Expression System (Sample Data Set)
Table 19.4 Capacity Analysis: Average Capacity for Microbial Expression System (Sample Data Set)
Table 19.5 Capacity Analysis: Global Contract Biomanufacturing Capacity
Table 20.1 Annual Biomanufacturing Capacity, 2022-2035 (Million Liters)
Table 20.2 ADC Therapeutics: Annual Demand for Outsourcing, 2022-2030 (in kilograms)
Table 20.3 ADC Therapeutics: Annual Supply for Outsourcing, 2022-2030 (in kilograms)
Table 23.1 List of Virtual Biopharmaceutical Companies
Table 24.1 Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best-selling Biologics
Table 26.1 Survey Analysis: Overview of Respondents
Table 26.2 Survey Analysis: Distribution of Respondents by Designation
Table 26.3 Survey Analysis: Biologics Manufacturing Expertise
Table 26.4 Survey Analysis: Scale of Manufacturing
Table 26.5 Survey Analysis: Location of Production Facilities
Table 26.6 Survey Analysis: Type of Expression System Used
Table 26.7 Survey Analysis: Type of Bioreactor Used
Table 26.8 Survey Analysis: Mode of Operation of Bioreactor
Table 29.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
Table 29.2 Biopharmaceutical CMOs: Distribution by Company Size
Table 29.3 Biopharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 29.4 Biopharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Table 29.5 Biopharmaceutical CMOs: Distribution by Company Size, Year of Establishment and Location of Headquarters
Table 29.6 Biopharmaceutical CMOs: Distribution by Type of Service(s) Offered
Table 29.7 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured
Table 29.8 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured and Location of Headquarters
Table 29.9 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured and Company Size
Table 29.10 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 29.11 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 29.12 Biopharmaceutical CMOs: Distribution by Type of Expression System Used
Table 29.13 Biopharmaceutical CMOs: Distribution by Type of Expression System Used and Location of Headquarters
Table 29.14 Biopharmaceutical CMOs: Distribution by Type of Bioreactor Used
Table 29.15 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactor
Table 29.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 29.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution of Type of Service(s) Offered
Table 29.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 29.19 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Expression System Used
Table 29.20 AGC Biologics: Annual Revenues FY 2017-Q1 2022 (JPY Billion)
Table 29.21 Catalent: Annual Revenues, FY 2017-9M 2022 (USD Million)
Table 29.22 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
Table 29.23 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2017-FY 2021 (JPY Billion)
Table 29.24 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Table 29.25 Patheon: Annual Revenues, FY 2017-FY 2021 (USD Million)
Table 29.26 Piramal Enterprises: Annual Revenues, FY 2017-FY 2021 (INR Crores)
Table 29.27 Boehringer Ingelheim: Annual Revenues, FY 2017-FY 2021 (EUR Billion)
Table 29.28 Lonza: Annual Revenues, FY 2017-FY 2021 (CHF Billion)
Table 29.29 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 29.30 Sandoz: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 29.31 WuXi Biologics: Annual Revenues, FY 2017-FY 2021 (RMB Million)
Table 29.32 Takara Bio: Annual Revenues, FY 2017-FY 2021 (JPY Million)
Table 29.33 Celltrion: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Table 29.34 Samsung Biologics: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Table 29.35 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Table 29.36 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Table 29.37 Antibody Drug Conjugates: Distribution by Status of Development
Table 29.38 Antibody Drug Conjugates: Distribution by Target Indication
Table 29.39 Key ADC Technology Providers: Distribution by Number of Candidates
Table 29.40 Stem Cell Therapies: Distribution by Phase of Development
Table 29.41 T-Cell Therapies: Distribution by Phase of Development
Table 29.42 Gene Therapies: Distribution by Stage of Development
Table 29.43 Gene Therapies: Distribution by Phase of Development
Table 29.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 29.45 Early-Stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 29.46 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 29.47 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 29.48 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Table 29.49 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 29.50 Biosimilars: Historical Trend of FDA Approval, 2015-2021
Table 29.51 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2021
Table 29.52 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2022
Table 29.53 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 29.54 Big Pharma Players: Distribution by Purpose of Initiative
Table 29.55 Big Pharma Players: Distribution by Type of Initiative
Table 29.56 Big Pharma Players: Distribution by Type of Expansion
Table 29.57 Big Pharma Players: Distribution by Scale of Operation
Table 29.58 Big Pharma Players: Distribution by Type of Biologic Manufactured
Table 29.59 Big Pharma Players: Distribution by Purpose of Initiative and Company
Table 29.60 Big Pharma Players: Distribution by Year and Type of Initiative
Table 29.61 Big Pharma Players: Distribution by Region of Expansion and Company
Table 29.62 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 29.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.64 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 29.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 29.66 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 29.67 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 29.68 Most Active Players: Distribution by Number of Partnerships
Table 29.69 Partnerships and Collaborations: Local and International Agreements
Table 29.70 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2022)
Table 29.71 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 29.72 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 29.73 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 29.74 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015-2022)
Table 29.75 Most Active Acquirers: Distribution by Number of Acquisitions
Table 29.76 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 29.77 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 29.78 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 29.79 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 29.80 Mergers and Acquisitions: Year-wise Trend of Deal Multiple Amount (USD Million)
Table 29.81 Recent Expansions: Cumulative Year-wise Trend, 2016-2022
Table 29.82 Recent Expansions: Distribution by Purpose of Expansion
Table 29.83 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 29.84 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 29.85 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 29.86 Recent Expansions: Distribution by Location of Expanded Facility
Table 29.87 Most Active Players: Distribution by Number of Recent Expansions
Table 29.88 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 29.89 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 29.90 Funding and Investment Analysis: Cumulative Year-wise Trend of Number of Funding Instances, 2016-2022
Table 29.91 Funding and Investment Analysis: Cumulative Year-wise Trend of Total Amount Invested, 2016-2022 (USD Million)
Table 29.92 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding
Table 29.93 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 29.94 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2016-2022
Table 29.95 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Continent-wise) (USD Million)
Table 29.96 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Country-wise) (USD Million)
Table 29.97 Most Active Players: Distribution by Number of Funding Instances
Table 29.98 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 29.99 Most Active Investors: Distribution by Number of Funding Instances
Table 29.100 Capacity Analysis: Distribution by Company Size
Table 29.101 Capacity Analysis: Distribution by Type of Expression System Used
Table 29.102 Capacity Analysis: Distribution by Scale of Operation
Table 29.103 Capacity Analysis: Distribution by Region
Table 29.104 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in North America
Table 29.105 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 29.106 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 29.107 Global Demand for Biopharmaceuticals, 2022-2035 (in kilograms)
Table 29.108 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Table 29.109 Demand and Supply Scenario for Biopharmaceuticals, 2022-2035 (Million Liters)
Table 29.110 Demand Analysis: Annual Demand for ADC Therapeutics (in kilograms), 2022-2030
Table 29.111 Global Demand for Cell Therapies, 2022-2030 (in terms of Number of Patients)
Table 29.112 Global Demand for Cell Therapies, 2022-2030 (Billion Cells)
Table 29.113 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2022-2042 (USD Million)
Table 29.114 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Table 29.115 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023: Distribution of CAPEX (USD Million)
Table 29.116 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023-2042: Distribution by OPEX (USD Million)
Table 29.117 Global Biopharmaceutical Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.118 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service(s) Offered, 2022 and 2035
Table 29.119 Biopharmaceutical Contract Manufacturing Market for APIs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.120 Biopharmaceutical Contract Manufacturing Market for FDFs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.121 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Table 29.122 Biopharmaceutical Contract Manufacturing Market for Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.123 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.124 Biopharmaceutical Contract Manufacturing Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.125 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.126 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
Table 29.127 Biopharmaceutical Contract Manufacturing Market for Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.128 Biopharmaceutical Contract Manufacturing Market for Microbial Cell-based Operations, Conservative, Base and Optimistic Scenarios 2022-2035 (USD Billion)
Table 29.129 Biopharmaceutical Contract Manufacturing Market for Other Expression System-based Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.130 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
Table 29.131 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.132 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.133 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
Table 29.134 Biopharmaceutical Contract Manufacturing Market for Small Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.135 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.136 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.137 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography
Table 29.138 Biopharmaceutical Contract Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.139 Biopharmaceutical Contract Manufacturing Market in the US, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.140 Biopharmaceutical Contract Manufacturing Market in Canada, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.141 Biopharmaceutical Contract Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.142 Biopharmaceutical Contract Manufacturing Market in Italy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.143 Biopharmaceutical Contract Manufacturing Market in Germany, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.144 Biopharmaceutical Contract Manufacturing Market in France, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.145 Biopharmaceutical Contract Manufacturing Market in Spain, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.146 Biopharmaceutical Contract Manufacturing Market in the UK, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.147 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.148 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.149 Biopharmaceutical Contract Manufacturing Market in China, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.150 Biopharmaceutical Contract Manufacturing Market in India, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.151 Biopharmaceutical Contract Manufacturing Market in South Korea, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.152 Biopharmaceutical Contract Manufacturing Market in Japan, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.153 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.154 Biopharmaceutical Contract Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.155 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.156 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market in 2022 (USD Billion)
Table 29.157 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Table 29.158 Survey Analysis: Distribution of Respondents by Company Type
Table 29.159 Survey Analysis: Distribution of Respondents by Location of Headquarters
Table 29.160 Survey Analysis: Distribution of Respondents by Designation
Table 29.161 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Table 29.162 Survey Analysis: Distribution by Scale of Manufacturing
Table 29.163 Survey Analysis: Distribution by Location of Production Facilities
Table 29.164 Survey Analysis: Distribution by Type of Expression System Used
Table 29.168 Survey Analysis: Distribution by Mode of Operation of Bioreactor

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3P Biopharmaceuticals
2. 3SBio
3. 4TEEN4 Pharmaceuticals
4. 53Biologics
5. AR BROWN
6. Aalto Scientific
7. AavantiBio
8. AB2 Bio
9. AbbVie
10. AbbVie Contract Manufacturing
11. AbCellera
12. AbClon
13. Abeona Therapeutics
14. ABL
15. ABL Bio
16. Abogen Biosciences
17. Abzena
18. AC Immune
19. Acasti Pharma
20. Accellta
21. Accinov
22. ACES Pharma
23. Achilles Therapeutics
24. Acticor Biotech
25. Adagene
26. AdAlta
27. Adaptimmune Therapeutics
28. AdaptVac
29. Adare Pharmaceuticals
30. ADC Biotechnology (Acquired by Sterling Pharma Solutions)
31. Adimmune
32. ADM Biopolis
33. Advanced Biotherapeutics Consulting
34. Advanced Cell Technology and Engineering
35. Advanced Scientifics (Acquired by Thermo Fisher Scientific)
36. Advaxis
37. Advent Bioservices
38. Aeras
39. Affibody
40. Affinita Biotech
41. Affinity Life Sciences
42. Affymetrix
43. Afton Scientific
44. AGC Biologics
45. Agilis Biotherapeutics
46. Agilux Laboratories
47. Airway Therapeutics
48. Ajinomoto Althea
49. Ajinomoto Bio-Pharma Services
50. Akorn
51. Akouos
52. Akron Biotech
53. Akshaya Bio
54. Alcami
55. Aldevron
56. Alexion
57. Alira Health
58. AllCells
59. Allele Biotechnology & Pharmaceuticals
60. Allergan
61. Allergy Therapeutics
62. Allevi
63. Alliance Protein Laboratories (Acquired by KBI Biopharma)
64. Alligator Bioscience
65. Almac
66. Almirall
67. Alphamab
68. Alteogen
69. Altimmune
70. Altor BioScience
71. Amaran Biotechnology
72. Amatsigroup (Acquired by Eurofins)
73. AmbioPharm
74. American Peptide Company (Acquired by Bachem)
75. Amgen
76. Ampersand Capital Partners
77. AM-Pharma
78. AMRI
79. Andes Biotechnologies
80. ANL Bio
81. Antabio
82. Anthos Therapeutics
83. apceth Biopharma
84. Aptevo Therapeutics
85. Aravive Biologics
86. Arcellx
87. Arch Biopartners
88. ArchiMed
89. Arcturus Therapeutics
90. Arcus Biosciences
91. Arecor
92. argenx
93. Arranta Bio
94. Aruvant Sciences
95. Asahi Kasei
96. ASC Therapeutics
97. Ash Stevens
98. Asher Biotherapeutics
99. ASLAN Pharmaceuticals
100. Aspire Health Science
101. Asterias Biotherapeutics
102. Astero Bio
103. Astorg
104. AstraZeneca
105. Asymchem
106. Asymptote (Acquired by GE Healthcare)
107. Atara Biotherapeutics
108. Athersys
109. aTyr Pharma
110. Aumgene Biosciences
111. Aurinia Pharmaceuticals
112. Austrianova
113. AutekBio
114. Autolus Therapeutics
115. Avecia (Acquired by Nitto Denko)
116. AveXis
117. Avid Bioservices
118. Avrio Biopharmaceuticals
119. Axcellerate Pharma
120. Axovant Gene Therapies
121. Babraham Bioscience Technologies
122. Baccinex
123. Bachem
124. BacThera
125. Batavia Biosciences
126. Battelle
127. Baxter
128. Baxter BioPharma Solutions
129. Bayer
130. Baylor College of Medicine
131. Baylor Institute for Immunology Research
132. Baylor Scott & White Research Institute (BSWRI)
133. BCN Peptides
134. Beam Therapeutics
135. BeiGene
136. Beijing Kawin Technology
137. Berkeley Lights
138. BeRNA Therapeutics
139. Bexion Pharmaceuticals
140. Bharat Biotech
141. BIA Separations (Acquired by Sartorius)
142. BIBITEC
143. BiBo Pharma
144. BINEX
145. Bio Elpida
146. Bio Farma
147. Bioasis Technologies
148. BioCell
149. BioCentriq
150. BioCina
151. BioConnection
152. Biodextris
153. Bio-Ess Laboratories
154. Biofabri
155. Biogen
156. BioInno Bioscience
157. Bioinova
158. BioInvent
159. Biological E.
160. BioMARC
161. Biomay
162. BioMeca
163. Biomedical Advanced Research and Development Authority (BARDA)
164. Biomeva (Acquired by AGC)
165. Biomunex
166. BiondVax Pharmaceuticals
167. Bionova Scientific
168. BioNTech
169. BioNTech IMFS
170. Bioqube Ventures
171. BiosanaPharma
172. BioSciencesCorp
173. biose
174. BioSig Technologies
175. Bio-Synthesis
176. BioTechnique
177. Biotecnol
178. BioVaxys Technology
179. BioVectra
180. Bioverativ
181. Biovian
182. Bioworkshops
183. BioXcellence
184. BioXpress Therapeutics
185. BJ Bioscience
186. BJP Laboratories
187. Bliss Biopharmaceutical
188. Bloom Science
189. Blue Stream Laboratories
190. bluebird bio
191. Bluejay Therapeutics
192. Boehringer Ingelheim
193. Boston Children’s Hospital
194. Boston Institute of Biotechnology
195. BPL Biologics
196. BrainStorm Cell Therapeutics
197. Brammer Bio
198. Brenus Pharma
199. BriaCell Therapeutics
200. Bright Peak Therapeutics
201. Bristol Myers Squibb
202. Bryllan
203. BSP Pharmaceuticals
204. Burrard Pharmaceuticals
205. Buzzard Pharmaceuticals
206. C3i Center
207. Caisson Biotech
208. Caladrius Biosciences
209. Calviri
210. Calypso Biotech
211. CANbridge
212. CANbridge Pharmaceuticals
213. Cancer Research Technology
214. Canton Biologics
215. Capricor Therapeutics
216. Capsugel
217. Captozyme
218. CARBOGEN AMCIS
219. CaroGen
220. Catalent Biologics
221. Catalyst Biosciences
222. Catapult Therapy TCR (Acquired by Cell Medica)
223. CDR-Life
224. Cedar Pharmaceuticals
225. Cell and Gene Therapy Catapult
226. Cell Culture Company
227. Cell Medica
228. Cell Therapies
229. Celladon
230. Cell-Easy
231. Cellectis
232. CELLforCURE
233. CellGenix
234. Cellin Technologies
235. CELLINK
236. Cellipont Bioservices
237. Cellpoint Bioservices (Formerly known as Performance Cell Manufacturing)
238. Celltrion
239. Cellular Biomedicine Group
240. Cellular Therapeutics
241. CellVec
242. Celonic
243. Celsion
244. Celsis (Acquired by Charles River Laboratories)
245. Cenexi
246. Centaur Biopharmaceutical Services
247. Center for Breakthrough Medicines
248. Center for Innovation in Advanced Development and Manufacturing
249. Centers for Disease Control and Prevention
250. Coalition for Epidemic Preparedness Innovations (CEPI)
251. Cerbios-Pharma
252. Cerium Pharmaceuticals
253. CEVEC Pharmaceuticals
254. Charles River Laboratories
255. Chemomab Therapeutics
256. ChemPartner
257. Chime Biologics
258. Chimeron Bio
259. China Regenerative Medicine International
260. Chinese Peptide Company
261. Chiome Bioscience
262. CHO Pharma
263. Chord Therapeutics (Acquired by Merck)
264. CiMaas
265. Cipla
266. CiRA Foundation
267. Citryll
268. Clean Biologics
269. Clean Cells
270. CMAB Biopharma
271. CMC Biologics
272. CMIC
273. Coalition for Epidemic Preparedness Innovations
274. Cobra Biologics
275. Cognate BioServices
276. Coherus BioSciences
277. Coldstream Laboratories
278. Columbia University
279. CombiGene
280. Contract Manufacturing & Development
281. Cook MyoSite
282. CordenPharma
283. Coretherapix
284. Covance
285. CPC Scientific
286. CPI
287. CR Pharmaceutical
288. CRC for Cell Therapy Manufacturing
289. Creative Biolabs
290. Crescendo Biologics
291. CRISPR Therapeutics
292. Cryoport
293. CSBio
294. CSL
295. CureCell
296. CureVac
297. Curia
298. Cytiva
299. CytoDyn
300. Cytosen Therapeutics
301. Cytovance Biologics
302. CyTuVax
303. Daiichi Sankyo
304. Dalton Pharma Services
305. Danaher
306. DanDrit Biotech
307. DaTaMabs
308. Decibel Therapeutics
309. Delphi Genetics
310. Denali Therapeutics
311. Dendreon
312. DeoBioSciences
313. Department of Defense
314. DiNAQOR
315. Disposable-Lab (Acquired by Eurofins)
316. DM Bio
317. Drugs for Neglected Diseases?initiative (DNDi)
318. Dyadic International
319. Dyax
320. Eden Biologics
321. Educell
322. EirGenix
323. Eisai
324. Elion Labs
325. Emendo Biotherapeutics
326. Emergent BioSolutions
327. Emerson
328. Encure Biopharma
329. Enimmune
330. Enleofen Bio
331. Enterobiome
332. Enzene Biosciences
333. Enzolytics
334. ERC Belgium
335. Erytech Pharma
336. Esco Aster
337. Etinpro
338. EuBiologics
339. Eucodis Bioscience
340. EUFETS
341. Eurocine Vaccines
342. Eurofins Scientific
343. Eurogentec
344. Euticals
345. EVER Pharma
346. evitria
347. Evologic Technologies
348. Excellos
349. ExCellThera
350. Exelead
351. Exelisis
352. Exelixis
353. Exothera
354. FairJourney Biologics
355. Fapon Biopharma
356. Faron Pharmaceuticals
357. FinVector
358. FloDesign Sonics
359. Florida Biologix
360. FluGen
361. Forecyte Bio
362. Formycon
363. For?Robin
364. Forty Seven (Acquired by Gilead Sciences)
365. Forum for Innovative Regenerative Medicine
366. Fred Hutchinson Cancer Research Center
367. Freeline Therapeutics
368. FUJIFILM Diosynth Biotechnologies
369. Fusion Antibodies
370. Fzata
371. Gadea Pharmaceutical (Acquired by AMRI)
372. Gallant Custom Laboratories
373. Gamida Cell
374. GC Cell
375. GC Pharma
376. GE Healthcare
377. Gedeon Richter
378. GeneCure Biotechnologies
379. GeneDesign
380. Genentech
381. GeneOne Life Science
382. Geneos Therapeutics
383. GeneQuantum Healthcare
384. GeneScience Pharmaceuticals
385. Genethon
386. Genexine
387. Genezen
388. GenIbet
389. GenIbet Biopharmaceuticals
390. Genmab
391. Genome & Company
392. Genopis
393. Genovior Biotech
394. Genprex
395. GenScript
396. GenScript ProBio
397. GigaGen
398. Gilead Sciences
399. Ginkgo Bioworks
400. Gladstone
401. GlycoSeLect
402. Glycotope
403. Goodwin Biotechnology
404. Government of Canada
405. Government of UK
406. GP Pharm
407. Grand River Aseptic Manufacturing
408. Great Point Partners
409. Green Cross LabCell
410. GreenLight Biosciences
411. GreenPak Biotech
412. Greffex
413. Grenoble Hospital
414. Griffith University
415. GSK
416. GT Biopharma
417. GTP Bioways
418. GTP Technology
419. Gubra
420. H.I.G. Capital
421. HaemaLogiX
422. HALIX
423. Hangzhou Redox BIO
424. Hansa Biopharma
425. Harbin Hou pu Tong tang Biotechnology
426. Harbour BioMed
427. Harpoon Therapeutics
428. Harpoon Therapeutics
429. HDT Bio
430. Heidelberg Pharma
431. Helixmith
432. Hemogenyx
433. Hepalink USA
434. Hepatic Cell Therapy Support
435. Hile Bio-Technology
436. Histocell
437. Hitachi Chemical
438. Hong Kong Institute of Biotechnology
439. Hookipa Biotech
440. Horizon Discovery
441. Horizon Pharma
442. Horizon Therapeutics
443. Hospira
444. Houston Methodist Research Institute
445. Humanigen
446. Hummingbird Bioscience
447. Hybio Pharmaceutical
448. Hycult Biotech
449. HYGEIA Group
450. IAVI
451. IBC Generium
452. Icagen
453. Ichnos Sciences
454. ID Pharma
455. IDT Biologika
456. I-Mab Biopharma
457. Immatics
458. Immune Pharmaceuticals
459. Immunitas Therapeutics
460. ImmunoCellular Therapeutics
461. Immunocore
462. ImmunoGenesis
463. Immunome
464. Immunomedics
465. ImmunoTek Bio Centers
466. Immutep (Formerly known as Prima BioMed)
467. Imperial College London
468. Imperial Innovations
469. In3Bio
470. IncoCell Tianjin
471. Indapta Therapeutics
472. Indian Immunologicals
473. IndyGeneUS AI
474. Inhibrx
475. InnoBation Bio
476. Innovation Network Corporation of Japan
477. Innovative Biotech
478. Innovative NeuroTechnologies
479. InnovaVector
480. Inovio Pharmaceuticals
481. Inpac Probiotics
482. INSERM-ANRS
483. Institute for Research
484. Integrated DNA Technologies
485. Integrity Bio
486. IntellectiveBio
487. International AIDS Vaccine Initiative
488. International Consortium
489. International Stem Cell Corporation
490. Intervacc
491. Intravacc
492. Invenra
493. Invetech
494. Iovance Biotherapeutics
495. iProgen Biotech
496. IQVIA
497. FUJIFILM Irvine Scientific
498. IsoPlexis
499. Istituto Biochimico Italiano Giovanni Lorenzini
500. Iveric Bio
501. JAFRAL
502. Janssen Pharmaceuticals
503. Japan Tissue Engineering
504. Japanese Society for Regenerative Medicine
505. Jeneil Biotech
506. JHL Biotech
507. Jitsubo
508. Jo Lab
509. Johns Hopkins University
510. Johnson & Johnson
511. JOINN Biologics
512. JOINN Laboratories
513. JSR
514. Jubilant HollisterStier
515. Juniper Pharmaceuticals
516. Juno Pharmaceuticals
517. Juno Therapeutics
518. Just-Evotec Biologics
519. JW CreaGene
520. JW Therapeutics
521. KABS Pharmaceutical Services
522. KAHR Medical
523. Kamat Pharmatech
524. Kanaph Therapeutics
525. Kanda BioTech
526. Kaneka Eurogentec
527. Karolinska Institutet
528. KBI Biopharma
529. Kemwell Biopharma
530. Kiadis Pharma
531. Kineta
532. Kite Pharma
533. Kite Pharma (Acquired by Gilead Sciences)
534. Kodiak Sciences
535. KOLON Life Science
536. KP Pharmaceutical Technology
537. KPC Pharmaceuticals
538. KUBio
539. Kytopen
540. Labyrinth BioPharma (Formely known as AB Biotechnology)
541. LakePharma
542. LamKap Bio
543. LAMPIRE Biological Laboratories
544. LaNova Medicines
545. Lava Therapeutics
546. Leanbio
547. LEUKOCARE
548. Levena Biopharma
549. LFB
550. Lipum
551. List Biological Laboratories
552. LNC Therapeutics
553. Lokon Pharma
554. Lonza
555. LSNE Contract Manufacturing
556. LucasPye BIO
557. Luina Bio
558. Lykan Bioscience
559. Lyophilization Services of New England
560. Lyophilization Technology
561. Lysogene
562. Mabion
563. MabPlex
564. MAbSilico
565. Mab-Venture Biopharma
566. MacroGenics
567. Maine Biotechnology
568. Malvern Panalytical
569. Massachusetts Eye and Ear
570. MassBiologics
571. MaSTherCell
572. Matica Biotechnology
573. MaxiVAX
574. Medeor Therapeutics
575. Medigene
576. MedImmune
577. MEDINET
578. Medisun Holdings
579. Medix Biochemica
580. MEMO Therapeutics
581. Menarini Biotech
582. Merck
583. Merck Millipore
584. Meridian Life Science
585. Mesoblast
586. Metastagen
587. Meteoric Biopharmaceuticals
588. MGB Biopharma
589. MicroBiopharm Japan
590. MicrofluidX
591. Mila’s Miracle Foundation
592. Milner Therapeutics Institute
593. Minaris Regenerative Medicine
594. Minneapolis Medical Research Foundation
595. Mitsubishi Gas Chemical
596. Moderna
597. Molecular Medicine
598. Molecular Partners
599. Morphotek
600. MSD
601. MTI-GlobalStem
602. Multispan
603. Mundipharma
604. Mycenax Biotech
605. Mylab Discovery Solutions
606. Najít Technologies
607. Namocell
608. Nan Fung
609. Nanotein Technologies
610. Naobios
611. National Cancer Center Japan
612. National Cancer Institute
613. National Center for Advancing Translational Sciences
614. National Health Research Institutes
615. National Heart, Lung and Blood Institute
616. National Institute of Allergy and Infectious Diseases
617. National Institutes of Health
618. Nature Technology
619. Navrogen
620. NBE-Therapeutics
621. NeoProgen
622. Neovacs
623. NeoVentures Biotechnology
624. Neuland
625. NeuroFx
626. NEUWAY Pharma
627. Nikon
628. Nikon CeLL innovation
629. Nitto Avecia Pharma Services
630. NIZO
631. Nobelpharma
632. Northway Biotech
633. Northway BiotechPharma
634. Nouscom
635. NovalGen
636. Novartis
637. Novasep
638. Novavax
639. Novex Innovations
640. NovoCodex Biopharmaceuticals
641. Numab
642. Numab Therapeutics
643. NYU Langone Health
644. OBI Pharma
645. Ontario Bioscience Innovation Organization (OBIO
646. Octane Biotech
647. Ocugen
648. Odylia
649. Ology Bioservices
650. Olon
651. Omeros
652. Omnia Biologics
653. OmniChem
654. Oncodesign
655. OncoOne
656. OncoQuest
657. OncoVent
658. Ondek
659. Ono Pharmaceutical
660. Oragenics
661. Orchard Therapeutics
662. Orgenesis
663. ORPEGEN Peptide Chemicals
664. Osaka University
665. OSE Immunotherapeutics
666. Osivax
667. Otsuka Pharmaceutical
668. Oxford BioMedica
669. Oxford BioTherapeutics
670. Oxford Genetics
671. Oxford MEStar
672. OXGENE
673. Pace Life Sciences
674. PacificGMP
675. PackGene Biotech
676. PaizaBio
677. Pall
678. Pall Corporation
679. Panacea Biotec
680. Panacea Pharmaceuticals
681. PanCELLa
682. Panolos Bioscience
683. Paragon Bioservices
684. Parker Institute for Cancer Immunotherapy
685. Particle Sciences
686. Passage Bio
687. PATH
688. Patheon
689. PaxVax
690. PCI Pharma Services
691. PCT
692. Peter MacCallum Cancer Centre
693. Petrovax
694. Pfizer
695. Pfizer CentreOne
696. Phanes Therapeutics
697. PharmAbcine
698. PharmaBio
699. PharmaCell
700. PharmaZell
701. Pharmicell
702. PhaseBio Pharmaceuticals
703. pHion Therapeutics
704. Pieris Pharmaceuticals
705. Pierre Fabre
706. Pinteon Therapeutics
707. Pionyr Immunotherapeutics
708. Piramal Pharma Solutions
709. Plasma Industries Belgium (Formerly known as CAF-DCF)
710. PlasmidFactory
711. Polaris Pharmaceuticals
712. Polpharma Biologics
713. Polymun Scientific
714. PolyPeptide Group
715. Portola Pharmaceuticals
716. Porton Biopharma
717. Praxis Pharmaceutical
718. Precirix
719. Precision Antibody
720. Precision NanoSystems
721. Prevail Therapeutics
722. PrimaPharma
723. ProbioFerm
724. ProBioGen
725. Probiotical
726. Probiotics Australia
727. Profectus BioSciences
728. Prokarium
729. Prometic Life Sciences
730. Propanc Biopharma
731. Proteon Therapeutics
732. Protexin
733. Provia Labs
734. PsiVac
735. PTC Therapeutics
736. PX'Therapeutics
737. Q-Biologicals
738. Quell Therapeutics
739. Quratis
740. Radimmune Therapeutics
741. Rare Trait Hope Fund
742. Recipharm
743. Refana
744. ReForm Biologics
745. REGENXBIO
746. Regulus Therapeutics
747. Relief Therapeutics
748. ReNeuroGen
749. Rentschler Biopharma
750. Rentschler Fill Solutions
751. Resilience
752. RevaTis
753. Revolo Biotherapeutics
754. RheinCell Therapeutics
755. RiboBio
756. Richter-Helm BioLogics
757. Ridgeway Biologicals
758. River Vision Development
759. Roche
760. Rocket Pharmaceuticals
761. Roslin Cell Therapies
762. RoslinCT
763. Rznomics
764. Saiba
765. Sam Chun Dang Pharm
766. Samsung Bioepis
767. Samsung BioLogics
768. SanBio
769. Sandoz
770. Sanofi
771. Sanofi Pasteur
772. Sanofi-Aventis
773. Sanpower
774. Santen Pharmaceutical
775. Sarepta Therapeutics
776. Sartorius Stedim Biotech
777. Scancell
778. SCD
779. Scientific Protein Laboratories
780. ScinoPharm
781. Scorpion Biological Services
782. Selecta Biosciences
783. Serendex Pharmaceuticals
784. Serum Institute of India
785. Servier
786. Shandong Luoxin Pharmaceutical
787. Shanghai Jiao Tong University
788. Shanghai Junshi Biosciences
789. Sheba Medical Center
790. Shenyang Sino-German Equipment Park
791. Shenzhen Bao’an Sino-German (Europe) Industrial Development 
792. Shenzhen Jianyi Biotechnology
793. Shenzhen JYMed Technology
794. Shilpa Biologicals
795. Shire
796. Showa Denko
797. Siam Bioscience
798. Siegfried
799. SillaJen
800. Singota Solutions
801. SIRION Biotech
802. Sistemic
803. SK Bioscience
804. Snapdragon Chemistry
805. Sonnet BioTherapeutics
806. Sorrento Therapeutics
807. Spicona
808. SpyBiotech
809. ST Pharm
810. Stanford University School of Medicine
811. STCube
812. Stelis Biosource
813. Stellar Biotechnologies
814. Stemmatters
815. Sterling Pharma Solutions
816. Stratophase
817. Sumagen
818. Sumitomo Dainippon Pharma
819. Summa Life Sciences
820. Sun Pharma
821. Surface Oncology
822. Surrozen
823. Suzhou Kintor Pharmaceuticals
824. Symbiosis Pharmaceutical Services
825. Symphogen
826. SynCo Bio Partners
827. Synimmune
828. Synklino
829. Synpromics
830. Synthace
831. Synthelis
832. Taisho Pharmaceutical
833. Taiwan Liposome Company
834. Takara Bio
835. Takeda
836. Taron Solutions
837. TCR2 Therapeutics
838. Tectron
839. Telix Pharmaceuticals
840. Tenboron
841. TeneoBio
842. Terumo
843. Terumo BCT
844. Teva Pharmaceuticals
845. Tevogen Bio
846. TG Therapeutics
847. The Chemistry Research Solution
848. The Michael J. Fox Foundation
849. The Wistar Institute
850. Themis Medicare
851. TheraCell Advanced Biotechnology
852. Therapure Biopharma
853. Theravectys
854. Thermo Fisher Scientific
855. ThermoGenesis
856. Thousand Oaks Biopharmaceuticals
857. Tianjin Pharmaceutical
858. TiGenix
859. Tillotts Pharma
860. Tizona Therapeutics
861. T-knife
862. Tmunity Therapeutics
863. Tonix Pharmaceuticals
864. TRACON Pharmaceuticals
865. TrakCel
866. Transgene
867. Translate Bio
868. Transporin
869. TranXenoGen
870. Treadwell Therapeutics
871. Trefoil Therapeutics
872. Trellis Bioscience
873. Tri-Institutional Therapeutics Discovery Institute
874. TRIANNI
875. Trieza Therapeutics
876. TriLink BioTechnologies
877. TRIO Pharmaceuticals
878. Triphase Accelerator
879. Trizell
880. Tsinghua University Innovation Center for Immune Therapy
881. Tube Pharmaceuticals
882. TxCell
883. UAS Labs
884. UGA Biopharma
885. UK Cystic Fibrosis Gene Therapy Consortium
886. Ultragenyx Pharmaceutical
887. UNC Lineberger Comprehensive Cancer Center
888. Unique Biotech
889. University College London
890. University of Aberdeen
891. University of Birmingham
892. University of California
893. University of Leeds
894. University of Manchester
895. University of Pennsylvania
896. University of Queensland
897. University of Reading
898. University of Sheffield
899. University of South Australian
900. University of Tokyo
901. Uppsala BIO
902. US Department of Defense
903. US Government
904. Vaccine and Infectious Disease Organization (VIDO)
905. Vaccine Manufacturing and Innovation Centre
906. Vaccitech
907. ValenzaBio
908. Valerius Biopharma
909. Valneva
910. Vanderbilt University Medical Center
911. VascuLogic
912. Vaxart
913. VBI Vaccines
914. VDDI Pharmaceuticals
915. Vectron Biosolutions
916. Verseau Therapeutics
917. Vetter Pharma
918. VGXI
919. Vibalogics
920. Vifor Pharma
921. Vigene Biosciences
922. Vineti
923. Vir Biotechnology
924. ViralGEN
925. Virchow Biotech
926. Virovek
927. Viscofan
928. VIVEbiotech
929. Vivoryon Therapeutics (Formerly known as Probiodrug)
930. Voyager Therapeutics
931. Vaccine Research Institute (VRI)
932. WACKER
933. Waisman Biomanufacturing
934. Walvax Biotechnology
935. West Biotherapy
936. WIL Research
937. Winclove Probiotics
938. WuXi AppTec
939. WuXi Biologics
940. Wuxi Griffin
941. Xbrane Biopharma
942. Xencor
943. XL-protein
944. Xpress Biologics
945. Xyphos Biosciences
946. Yapan Bio
947. Yposkesi
948. Yuhan
949. Zealand Pharma
950. Zelluna Immunotherapy
951. Zhejiang Hisun Pharmaceutical
952. Zhejiang Teruisi Pharmaceutical
953. Zhittya Genesis Medicine
954. Ziopharm Oncology
955. Zumutor Biologics
956. Zymeworks
957. Zyngenia
958. ZyVersa Therapeutics